Brief: Lipidor Updates On Phase III Clinical Study

Lipidor AB

29/09/2022 07:15

Sept 29 (Reuters) - Lipidor AB  LIPI.ST :
    * UPDATES ON PHASE III CLINICAL STUDY OF PSORIASIS CANDIDATE
AKP02
    * DATA IS ESTIMATED TO BE AVAILABLE FOR ANALYSIS BY OUR
STATISTICAL PARTNER IN MID-OCTOBER
    * COMPANY ASSESSES THAT STUDY'S TOPLINE RESULTS CAN BE
PRESENTED
DURING SECOND HALF OF OCTOBER
    * PRIMARY OBJECTIVE OF PHASE III STUDY IS TO DEMONSTRATE
GOOD
THERAPEUTIC EFFICACY FOR TREATMENT OF MILD TO MODERATE PSORIASIS
ON BOTH BODY AND SCALP

Source text for Eikon:  ID:nMFN3gVfzH 
Further company coverage:  LIPI.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))